Lakefront Biotherapeutics NV
Lakefront Biotherapeutics develops gamgertamig, a BCMAxCD3 T-cell engager in clinical development for autoimmune diseases.
6-KNov 16Latest SEC filing
Nov 12Latest story
November 2026
October 2026
August 2026
July 2026
Lakefront Biotherapeutics develops gamgertamig, a BCMAxCD3 T-cell engager in clinical development for autoimmune diseases.
November 2026
October 2026
August 2026
July 2026